Dr. Siegel on the Importance of Bisphosphonates

Video

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates

David S. Siegel, MD, PhD, chief, Multiple Myeloma at John Theurer Cancer Center, on the importance of bisphosphonates for managing bone health in patients with multiple myeloma.

Related Videos
Elias Jabbour, MD
Shruti Tiwari, MD
Jeffrey P. Townsend, PhD
Marina Baretti, MD
George R. Simon, MD, FACP, FCCP
Saad Z. Usmani, MD, MBA, FACP, FASCO
Rebecca Kristeleit, BSc, MBChB, MRCP, PhD
Don S. Dizon, MD
Rohan Garje, MD
Sarah E. S. Leary, MD, MS, attending physician, medical director, Pediatric Brain Tumor Program, Seattle Children’s Hospital; professor, Department of Pediatrics, University of Washington School of Medicine
Related Content
US FDA

FDA Grants Breakthrough Therapy Designation to Ziftomenib in NPM1-Mutant AML

April 22nd 2024
Article
OncLive On Air

Revisit the OncLive On Air Episodes From February 2024

March 18th 2024
Podcast
Bradley J. Monk, MD, FACS, FACOG, Florida Cancer Specialists & Research Institute

FAK Inhibition Emerges as a Potential Complementary Treatment Pathway

April 22nd 2024
Article
Matthew Lunning, DO, FACP

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023
Podcast
OncLive On Air

Revisit Every OncLive On Air Episode from March 2024

April 19th 2024
Article
FDA

FDA Requires Boxed Warning for Risk of T-Cell Malignancies With Approved CAR T-Cell Therapies

April 19th 2024
Article